- Home
- GVH vs INAB Comparison
GVH vs INAB Comparison
Compare GVH & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GVH | INAB |
|---|---|---|
| Founded | 2016 | 2016 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8M | 10.6M |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GVH | INAB |
|---|---|---|
| Price | $3.31 | $1.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $80.00 | ★ $108.00 |
| AVG Volume (30 Days) | 18.0K | ★ 52.2K |
| Earning Date | 09-09-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 11.95 | N/A |
| Revenue | ★ $21,878,867.00 | N/A |
| Revenue This Year | $141,706.20 | N/A |
| Revenue Next Year | $3.35 | N/A |
| P/E Ratio | $0.28 | ★ N/A |
| Revenue Growth | ★ 24.52 | N/A |
| 52 Week Low | $3.30 | $1.53 |
| 52 Week High | $364.00 | $12.53 |
Technical Indicators
Market Signals| Indicator | GVH | INAB |
|---|---|---|
| Relative Strength Index (RSI) | 26.40 | 42.30 |
| Support Level | $3.33 | $1.67 |
| Resistance Level | $4.18 | $1.87 |
| Average True Range (ATR) | 0.22 | 0.11 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 4.15 | 2.28 |
Price Performance
Historical ComparisonAbout GVH Globavend Holdings Limited
Globavend Holdings Ltd is an e-commerce logistics provider, it provides integrated cross-border logistics services from Hong Kong to Australia and New Zealand, where it provides customers with a one-stop solution from parcel consolidation to air freight forwarding, customs clearance, on-carriage parcel transportation and delivery. It operates in logistics and freight forwarding industry, which involves the provision of services such as freight transport, freight forwarding, warehouse management, and distribution.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.